Artivion, Inc. Files 8-K on Financials
Ticker: AORT · Form: 8-K · Filed: May 6, 2024 · CIK: 784199
| Field | Detail |
|---|---|
| Company | Artivion, Inc. (AORT) |
| Form Type | 8-K |
| Filed Date | May 6, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-K, operations
TL;DR
ARTIVION filed an 8-K on May 6th detailing financial results. Check it out.
AI Summary
Artivion, Inc. filed an 8-K on May 6, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits related to its business operations. The company, formerly known as Cryolife Inc., is incorporated in Delaware and headquartered in Kennesaw, Georgia.
Why It Matters
This 8-K filing provides crucial updates on Artivion's financial performance and operational status, which is essential for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- ARTIVION, INC. (company) — Registrant
- Cryolife Inc. (company) — Former company name
- May 6, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Kennesaw, Georgia (location) — Principal executive office
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Artivion, Inc.'s results of operations and financial condition, including financial statements and exhibits.
When was this 8-K report filed?
This 8-K report was filed on May 6, 2024.
What was Artivion, Inc. formerly known as?
Artivion, Inc. was formerly known as Cryolife Inc.
Where is Artivion, Inc.'s principal executive office located?
Artivion, Inc.'s principal executive office is located at 1655 Roberts Boulevard, N.W., Kennesaw, Georgia 30144.
What is the SIC code for Artivion, Inc.?
The Standard Industrial Classification (SIC) code for Artivion, Inc. is 3841, which corresponds to Surgical & Medical Instruments & Apparatus.
Filing Stats: 730 words · 3 min read · ~2 pages · Grade level 10.7 · Accepted 2024-05-06 16:14:15
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value AORT NYSE Indicate by check
Filing Documents
- aort-20240506.htm (8-K) — 28KB
- aort-2024x8k33124ex991.htm (EX-99.1) — 299KB
- imagea.jpg (GRAPHIC) — 17KB
- 0000784199-24-000169.txt ( ) — 496KB
- aort-20240506.xsd (EX-101.SCH) — 2KB
- aort-20240506_lab.xml (EX-101.LAB) — 22KB
- aort-20240506_pre.xml (EX-101.PRE) — 13KB
- aort-20240506_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition On May 6, 2024, Artivion, Inc. ("Artivion") issued a press release announcing its financial results for the first quarter ended March 31, 2024. Artivion hereby incorporates by reference herein the information set forth in its press release dated May 6, 2024, a copy of which is attached hereto as Exhibit 99.1. Except as otherwise provided in the press release, the press release speaks only as of the date of such press release and it shall not create any implication that the affairs of Artivion have continued unchanged since such date. The information provided pursuant to this Item 2.02 is to be considered "furnished" pursuant to Item 2.02 of Form 8-K and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, nor shall it be deemed incorporated by reference into any of Artivion's reports or filings with the Securities and Exchange Commission, whether made before or after the date hereof, except as expressly set forth by specific reference in such report or filing. Except for the historical information contained in this report, the statements made by Artivion are forward-looking statements that involve risks and uncertainties. All such statements are subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Artivion's future financial performance could differ significantly from the expectations of management and from results expressed or implied in the press release. Please refer to the last paragraph of the text portion of the press release for further discussion about forward-looking statements. For further information on risk factors, please refer to "Risk Factors" contained in Artivion's most recently filed Form 10-K and its subsequent filings with the Securities and Exchange Commission, as w
01(d) Exhibits
Item 9.01(d) Exhibits (d) Exhibits. Exhibit Number Description 99.1 * Press Release dated May 6, 2024. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). * Furnished herewith, not filed. -2-
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, Artivion, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 6, 2024 ARTIVION, INC. By: /s/ Lance A. Berry Name: Lance A. Berry Title: Chief Financial Officer, and Executive Vice President, Finance -3-